Scarica l'app Stockscreener
29.27
35.92%
7.4702
Precedente Chiudi:
$21.80
Aprire:
$21.89
Volume 24 ore:
456.24K
Relative Volume:
0.43
Capitalizzazione di mercato:
$46.96M
Reddito:
-
Utile/perdita netta:
$-38.35M
Rapporto P/E:
-20.19
EPS:
-1.45
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
+30.93%
1M Prestazione:
+35.79%
6M Prestazione:
+802.83%
1 anno Prestazione:
+542.73%
Intervallo 1D:
$21.89
$29.73
Intervallo di 1 settimana:
$19.85
$29.73
Portata 52W:
$2.01
$38.33
Galecto Inc Stock (GLTO) Company Profile
Nome
Galecto Inc
Settore
Industria
Telefono
45-70-70-52-10
Indirizzo
75 STATE STREET, BOSTON
Compare GLTO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
29.35 | 34.88M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.26 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.78 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.51 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.11 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.23 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Guggenheim | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | BofA Securities | Buy |
| 2020-11-23 | Iniziato | Credit Suisse | Outperform |
| 2020-11-23 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Galecto Inc Borsa (GLTO) Ultime notizie
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Dividend Watch: Can Galecto Inc lead its sector in growthEarnings Miss & High Conviction Buy Zone Picks - baoquankhu1.vn
Galecto prices $275 million public offering at $19 per share By Investing.com - Investing.com Nigeria
Galecto Prices Upsized Public Offering to Fund DMR-001 - TipRanks
Galecto Signs Underwriting Agreement With Jefferies and Leerink Partners - TradingView
Galecto shares fall after $275 million equity raise at discount By Investing.com - Investing.com South Africa
GLTO: Key Managers Involved in Recent Offering - GuruFocus
Galecto to raise USD 275m in share issue - medwatch.com
Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down - Nasdaq
Cancer drug developer Galecto raises $275M in stock sale - Stock Titan
Hans Schambye resigns from Galecto – takes top position at Boost Pharma - medwatch.com
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - 富途牛牛
Galecto Prices $275 Million Offering - marketscreener.com
Galecto Announces Pricing of $275 Million Underwritten Public Offering - The Manila Times
Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Galecto announces pricing of $275 million underwritten public offering - marketscreener.com
Galecto Announces Pricing of $275 Million Underwritten Public Offering - GlobeNewswire Inc.
Galecto announces public offering of common stock and preferred shares By Investing.com - Investing.com Nigeria
Hans Schambye on Galecto exit: It happened by mutual agreement - medwatch.com
Galecto stock falls after announcing public offering of common stock By Investing.com - Investing.com India
Galecto stock falls after announcing public offering of common stock - Investing.com
Galecto (GLTO) Files Automatic Mixed Securities Shelf - GuruFocus
Cancer drug developer Galecto plans stock sale to fund antibody trials - Stock Titan
Galecto CEO Transition and Major Shareholder-Approved Restructuring - TipRanks
Galecto announces CEO transition, share authorization increase, and shareholder approvals - Investing.com India
Galecto (NASDAQ: GLTO) CEO departs amid big share increase and Cayman move - Stock Titan
Returns Recap: How sensitive is Galecto Inc to inflation2025 Market Outlook & High Yield Equity Trading Tips - baoquankhu1.vn
Galecto (NASDAQ:GLTO) Raised to Strong-Buy at Lifesci Capital - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
Growth Report: Will Galecto Inc announce a stock splitJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - baoquankhu1.vn
How sensitive is Galecto Inc to inflationTrade Performance Summary & Daily Momentum Trading Reports - baoquankhu1.vn
Galecto Showcases New mutCALR MPN Pipeline at JPM - TipRanks
Risk Report: Is dMY Squared Technology Group Inc Equity Warrant likely to announce a buybackJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Is Galecto Inc a stock for growth or value investorsJuly 2025 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
Fund Flows: Should I set a stop loss on CNFR2025 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
Exit Recap: What is Dow Incs book value per sharePortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Is Galecto Inc. stock supported by innovation pipelineTechnical Breakout Signals & Maximize Gains Professionally - Bollywood Helpline
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Movement Recap: Is Galecto Incs ROIC above industry averageJuly 2025 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Galecto (GLTO) Price Target Increased by 13.89% to 41.82 - Nasdaq
Investment Recap: Can Galecto Inc stock double in next 5 yearsEarnings Recap Report & Safe Entry Point Alerts - Bộ Nội Vụ
Galecto on track to submit IND for mutCALR antibody by mid-2026 - Investing.com Nigeria
Galecto on track to submit IND for mutCALR antibody by mid-2026 By Investing.com - Investing.com India
Galecto (GLTO) Sets Ambitious Clinical Milestones for 2026 - GuruFocus
Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
Galecto, Inc. Reports Strategic Shift and Financial Results - MSN
Galecto Completes Acquisition of Damora Therapeutics - MSN
Galecto (NASDAQ:GLTO) Upgraded at Leerink Partnrs - Defense World
What risks investors should watch in Galecto Inc. stock2025 Year in Review & Consistent Growth Equity Picks - ulpravda.ru
Is Galecto Inc. stock attractive for hedge fundsJuly 2025 Breakouts & Daily Price Action Insights - Улправда
Galecto Inc Azioni (GLTO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Galecto Inc Azioni (GLTO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
| Schambye Hans T. | Chief Executive Officer |
Jul 03 '25 |
Sale |
3.38 |
735 |
2,484 |
4,022 |
| Winslow Garrett | General Counsel |
Jul 03 '25 |
Sale |
3.39 |
260 |
881 |
1,429 |
| Firmani Lori | Interim CFO |
Jul 03 '25 |
Sale |
3.39 |
147 |
498 |
692 |
0.06%
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):